Non-alcoholic fatty liver disease (NAFLD) has for years been the most common liver disease worldwide. In 2016, the prevalence of NAFLD was estimated to be approximately 25 % [1], and recent reports suggest that the overall prevalence in 2023 has increased to 30 % with regional differences [2,3]. NAFLD can progress to non-alcoholic steatohepatitis (NASH) with development of fibrosis, and further progression to cirrhosis with its complications including an increased risk of primary liver cancer. Patients with advanced liver fibrosis have increased risk of liver-related morbidity and mortality, whereas cardiovascular disease (CVD) is the leading cause of death in any stage of NAFLD [4].
